Cognition Therapeutics Inc (CGTX): R&D Expense
$37.19M
Year ended 2025-12-31
$26.14M
Trailing 12 months to 2026-06-30
+7.0%
3-year compound annual growth
+23.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $37.19M | -10.8% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $41.68M | +12.0% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $37.20M | +22.7% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $30.32M | +63.3% | 2024-03-26, From 2022-01-01 |
| 2021-12-31 | $18.57M | +44.1% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $12.89M | n/a | 2022-03-30, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Cognition Therapeutics Inc (CGTX) | 2025-12-31 | $37.19M | -10.8% |
| PharmaCyte Biotech, Inc. (PMCB) | 2026-04-30 | $391.3K | -10.7% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $37.59M | +9.4% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $39.75M | +23.7% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $112.67M | +1.0% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $35.33M | -4.1% |
| Passage BIO, Inc. (PASG) | 2025-12-31 | $23.28M | -42.1% |
| Elutia Inc. (ELUT) | 2025-12-31 | $4.16M | +38.9% |
| Jasper Therapeutics, Inc. (JSPR) | 2025-12-31 | $63.10M | +13.0% |
Compare CGTX, PMCB, SNTI, OCGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗